

(51) International Patent Classification:
A61K 31/7032 (2006.01)

(21) International Application Number:

PCT/US2014/029569

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:



English

(30) Priority Data:

61/799,519 15 March 2013 (15.03.2013) US

(71) Applicant: **GARNET BIOTHERAPEUTICS, INC.**
[US/US]; 490 Lapp Road, Malvern, PA 19355 (US).(72) Inventors: **RAGAGLIA, Vanessa**; 123 Spring Tree Drive,
Newton Square, PA 19073 (US). **MADANLAL
SHARMA, Vandana**; 9801 Germantown Pike, Apt. 120,
Lafayette Hill, PA 19444 (US).(74) Agent: **BOUCHEZ, Cynthia M.**; Fanelli Haag & Kilger
PLLC, 1300 I Street, N.W., Suite 850 West, Washington,
DC 20005 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: **GANGLIOSIDE COMPOSITIONS****FIG. 1A****FIG. 1B**(57) **Abstract:** The invention provides novel gangliosides and mixtures of novel gangliosides and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, *e.g.*, GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of *e.g.*, human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, *e.g.*, GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, *e.g.*, GM1. Methods of quantifying gangliosides, *e.g.*, GM1 in cell culture are also provided.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*